Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Recruiting
18 years - 100 years
All
42 participants needed
1 Location

Brief description of study

The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.

Detailed description of study

Researchers will collect a blood sample and information from participants' medical record. Participants will receive stereotactic radiosurgery (SRS) to a dose according to the size of their metastatic brain disease. Participants will undergo normal clinical (examinations) and radiographic (brain MRI with contrast) follow-up one month after SRS and every three months after SRS for a full year.

None of the procedures participants undergo will be experimental; all are standard of care. However, the lower dose of stereotactic radiosurgery they will receive is not standard of care.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Metastases,brain tumor,metastasis,tumor
  • Age: 18 years - 100 years
  • Gender: All

Individuals at least 18 years of age with 1-10 solid tumor brain metastases.

Individuals with an existing autoimmune disease will not be eligible.

Updated on 04 Aug 2024. Study ID: 1906336263

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team